Skip to main content
. 2023 Feb 2;6(2):e2254221. doi: 10.1001/jamanetworkopen.2022.54221

Figure 2. Survival Outcomes for Patients With Clonal Hematopoiesis (CH) Alterations Annotated as Likely Putative Drivers (CH-PD).

Figure 2.

Kaplan-Meier curves are shown for overall survival (OS) for patients with metastatic esophagogastric cancer (EGC) and colorectal cancer (CRC) based on CH-PD status (A and B) and for progression-free survival (PFS) among patients with metastatic EGC and CRC who were treated with immune checkpoint blockade (ICB), based on CH-PD status (C and D). Kaplan-Meier estimates of OS and PFS were compared using a log-rank test.